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Abstract
Neurodegenerative disease encompasses a wide range of disorders afflicting the central and peripheral nervous systems and 
is a major unmet biomedical need of our time. There are very limited treatments, and no cures, for most of these diseases, 
including Alzheimer’s Disease, Parkinson’s Disease, Huntington Disease, and Motor Neuron Diseases. Mouse and other 
animal models provide hope by analysing them to understand pathogenic mechanisms, to identify drug targets, and to develop 
gene therapies and stem cell therapies. However, despite many decades of research, virtually no new treatments have reached 
the clinic. Increasingly, it is apparent that human heterogeneity within clinically defined neurodegenerative disorders, and 
between patients with the same genetic mutations, significantly impacts disease presentation and, potentially, therapeutic 
efficacy. Therefore, stratifying patients according to genetics, lifestyle, disease presentation, ethnicity, and other parameters 
may hold the key to bringing effective therapies from the bench to the clinic. Here, we discuss genetic and cellular humanised 
mouse models, and how they help in defining the genetic and environmental parameters associated with neurodegenerative 
disease, and so help in developing effective precision medicine strategies for future healthcare.
Introduction
Neurodegenerative diseases are characterised by progressive 
loss of neuronal subsets in the brain or spinal cord and afflict 
millions worldwide. These disorders are a leading cause of 
premature death globally, and have devastating social and 
personal costs to those affected and those who are close to 
them (Livingston et al. 2017). Dementia—the dysfunction/
loss in multiple cognitive areas that can arise from neuro-
degeneration—has reached pandemic proportions, afflicting 
50 million people in 2018, with the annual economic cost 
currently estimated at $1 trillion (Patterson 2018). Cases 
are on course to triple by 2050 largely due to our ageing 
population, with dramatically increased prevalence in those 
over 65 years of age (Patterson 2018).
Neurodegeneration is not a disease of the relatively afflu-
ent—dementia incidence is plateauing in high-income coun-
tries, but increasing in low- and middle-income countries, 
which have poorer access to healthcare and education (Pat-
terson 2018). Neurodegeneration is also not necessarily a 
disorder of ageing: a minority of neurodegenerative disease 
affects even the very young; for example, the single biggest 
genetic killer of infants remains type 1 spinal muscular atro-
phy (SMA) with an incidence of up to 1 in 6000 newborns 
in different populations worldwide (Sugarman et al. 2012). 
Even typically late-onset diseases can occur, exceptionally, 
in young people. Amyotrophic lateral sclerosis (ALS) has 
been described in 11-year old children; Alzheimer’s disease 
(AD) typically occurs in the 4th decade of life in people who 
have Down syndrome (DS); and Parkinson’s disease (PD) 
can manifest before the age of 30 (Conte et al. 2012; Trinh 
et al. 2019; Wiseman et al. 2015).
Currently, we have at best very limited therapeutic 
options for most neurodegenerative disorders, and cures for 
none of them. However, this bleak outlook may be changing 
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slowly and there is hope on the far horizon for at least some 
patients, with the advent of new therapies such as the use 
of antisense oligomers, gene therapies, antibody therapies, 
and stem cell therapeutics, in addition to conventional small 
molecules.
However, human and mouse phenotypes result from a 
largely undefined mix of genetics, environment, ageing, and 
stochastic effects, all of which need to be investigated to 
determine how to best treat and prevent disease. Neurode-
generation has a heterogeneous manifestation, so even in 
cases where known genetic mutation is causal for disease, 
we still only understand a small part of the whole picture of 
pathogenesis. For example, a triplet repeat expansion in the 
Huntingtin gene causes ~ 100% Huntington disease (HD), 
and while the size of this expansion largely determines age 
of disease onset, other alleles in the genetic background also 
modulate this timepoint (Long et al. 2018).
Neurodegenerative diseases, even the genetic forms, have 
complex etiologies, so they will require stratified treatments. 
Therefore, to create these treatments, we need real world 
data from human populations, which is usually highly vari-
able and noisy. We also need models we can manipulate, 
to help us tease out mechanistic insight into disease, and to 
assess therapies. This is particularly challenging for the late-
onset disorders in which disease typically manifests after 
many decades with no presymptomatic indications that we 
know of.
Different model systems provide different information 
and insights, but all are important for building the picture 
of pathomechanism. This includes in vitro systems, such 
as using human neurons produced from human pluripotent 
stem cells (PSCs, derived from embryos) or induced pluripo-
tent stem cells (iPSCs), and in vivo systems, such as animal 
models of human disease. These animals may model genetic 
forms of neurodegeneration, or have alleles that modulate 
disease manifestation, or be exposed to varied environments 
to assess effects on disease outcome (Hockly et al. 2002).
All research results from model systems must be vali-
dated in the human population, which is considerably more 
variable than any laboratory system. The long-term goals are 
to find treatments and ultimately cures that work in different 
individuals and also, critically, to use these in real world 
healthcare systems where cost-effectiveness and realistic 
medical regimes are the only options.
Precision medicine: contributions from the mouse
Precision medicine refers to an evidence-based approach to 
healthcare, in which the best treatment for an individual is 
chosen based on their genetic/epigenetic make up and other 
features such as their microbiome, age, nutrition, lifestyle, 
and specific biomarkers. Clearly, the more we understand, 
the more we can stratify treatments into the correct patient 
sub-groups, not just by genetics but by all other factors that 
make us distinctive individuals (Fig. 1).
To create precision medicine strategies requires a sys-
tems-based approach (Berlin et al. 2017), very large datasets, 
new algorithms, machine learning, many different types of 
data input, combined with rigorous statistical analysis to 
determine what is optimal in different sub-groups—and this 
can include even lifestyle changes such as in diet or exercise. 
The size of the problem means that large collaborative net-
works of different clinical, translational, basic science, and 
computational specialists are required to contribute data and 
to analyse different outcomes; for review see (Strafella et al. 
2018). There also remains an important role for the labora-
tory researchers drilling into pathomechanism, including 
those working with mouse models.
This review focuses on a specific type of mouse model, 
which is increasingly used in research: the humanised 
mouse. We discuss two types of humanised mouse—genetic 
and cellular humanised models and their different contribu-
tions to precision medicine for neurodegeneration.
Mice are not human but we can humanise them
Despite many similarities, mice are obviously different from 
humans at all levels. Size, anatomy, neuroanatomy, lifespan, 
heart rate, reproductive capacity, and responses to drugs are 
clearly species specific and affect disease manifestation. 
Even at the genetic level, we do not share exactly the same 
set of genes: roughly 1% of mouse genes are not present in 
humans and vice versa (Mouse Genome Sequencing Con-
sortium et al. 2002). Plus, humans have slightly more splice 
isoforms on average per gene (3.4 isoforms per protein cod-
ing gene) than mice (2.4) (Lee and Rio 2015). Nevertheless, 
we are separated by only 75 million years of evolution and 
biochemical mechanisms are broadly conserved between our 
species, and so mouse models have been a fruitful resource 
Fig. 1  An illustration of the role humanised mouse models play in the 
development of new precision and personalised medicine strategies
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for understanding human disease [noting that more than 20 
Nobel Prizes have been awarded for research primarily using 
mice (Festing and Fisher 2000)].
However, one way of potentially improving mouse mod-
els for studying human disease and neurodegeneration is to 
make the mice more ‘human’ either in terms of gene con-
tent by incorporating human DNA into the mouse genome 
(genetic humanisation) and/or cellular make up by engraft-
ing human cells into mouse tissues (cellular humanisation). 
Remarkably, both approaches were pioneered over 30 years 
ago (Brundin et al. 1986; Gordon and Ruddle 1981; Gumpel 
et al. 1987; Stromberg et al. 1986; Wagner et al. 1981).
Genetic humanisation: incorporation of human DNA 
into the mouse genome
The reasons for humanising at the DNA level are so that 
mouse models express genes and proteins analogous to those 
found in people—perhaps with the human splice isoforms 
or with the human protein biochemistry that may be subtly 
but critically different from mouse protein biochemistry. For 
example, tauopathies are characterised by deposition of tau 
protein, encoded by the MAPT (microtubule-associated pro-
tein tau) gene, and these include frontotemporal dementia 
(FTD), corticobasal degeneration, progressive supranuclear 
palsy, Pick’s disease, and other rarer neurodegenerative dis-
orders (Goedert et al. 2017). Humans express six tau iso-
forms in adult brain via alternative splicing, whereas mice 
express different isoforms in a different ratio—and this is 
critical for mouse modelling because human monogenic 
tauopathies can arise from MAPT mutations that affect the 
primary protein sequence and/or the splice isoform ratios 
(Goedert et al. 2017). Therefore, human MAPT sequences 
are required to model human tauopathies and so almost 
all mouse models of tau deposition are transgenic animals 
expressing the human gene.
Genetic humanisation can be achieved through a number 
of different strategies (Table 1). Injection of plasmids or 
artificial chromosome vectors into mouse zygotes results 
in the random genomic integration of human transgenes. 
This approach was used to generate the earliest mice cre-
ated with human transgenes (Gordon and Ruddle 1981; 
Wagner et al. 1981), and is still frequently used to intro-
duce human transgenes harbouring pathogenic mutations. 
Transgenic models have been the bedrock of neurodegen-
eration research, and have contributed important results for 
understanding human disease. However, they have some key 
features which we must consider, including that transgenes 
concatermerise when they insert into the genome, which 
they do randomly. Therefore, most transgenics, whether 
made from cDNA or genomic DNA, in plasmids or larger 
constructs, tend to be in multiple copies and thus overex-
press the protein of interest. Furthermore, several transgenic 
models utilise a non-endogenous promoter, such as the 
prion promoter, that can also lead to increased expression 
over endogenous levels. Overexpression can be helpful in 
that it may increase the rate of phenotype progression, as 
with the most widely used ALS mouse model, the SOD1-
G93A humanised transgenic mouse (Gurney et al. 1994). 
‘High-copy’ mice reach humane endpoint on commonly 
used genetic backgrounds before ~ 140 days, whereas ‘low-
copy’ animals, which are identical apart from having deleted 
much of the transgene array, take up to 9 months to reach 
humane endpoint (Acevedo-Arozena et al. 2011). Moreover, 
in the majority of transgenic models, the human sequence is 
expressed together with the mouse endogenous gene. Many 
genes/proteins, including the ALS-associated RNA-binding 
proteins, are highly dosage-sensitive, and so overexpression 
of even wildtype protein gives phenotypes that may not be 
related to the disease phenotype arising from mutation. This 
is the case for mutation in TARDBP encoding the TDP-43 
protein, FUS encoding the fused in sarcoma protein, and 
several other ‘ALS proteins’ [reviewed in (De Giorgio et al. 
2019)].
Genome engineering technologies allow genetic human-
isation at predefined genomic sites to create humanised 
knock-in mice, made through targeting via homologous 
recombination in mouse embryonic stem cells or directly 
in zygotes via CRSIPR/Cas9 genome-editing technologies. 
One knock-in humanisation approach is the insertion of 
human sequences into non-endogenous ‘safe harbour’ loci—
so named because targeted insertion at these loci generally 
does not affect the viability or fertility of the mouse. Rosa26 
is one commonly used ‘safe harbour’ locus, which has been 
used to produce a number of neurodegeneration-relevant 
transgenic lines, for example, TDP-43-M337V (ROSA26) 
mice, which express a pathological TARDBP human gene 
under the control of the human TARDBP promoter (Gordon 
et al. 2019). While expressed at relatively low levels com-
pared to transgenic models, the precise impact of expression 
at Rosa26 on cellular and temporal expression is unclear.
‘Physiological’ models are those that maintain gene-of-
interest expression at endogenous levels (in the appropri-
ate cellular and temporal context). These include mutants 
generated by random N-ethyl-N-nitrosourea mutagenesis 
of the mouse genome, for example, to produce the Sod1-
D83G mouse, which has an identical mutation (aspartic 
acid mutated to glycine at residue 83 ‘D83G’ of superoxide 
dismutase 1) as found in human SOD1-ALS families (Joyce 
et al. 2015). Alternatively, ‘physiological’ models can be 
engineered by the targeted knock-in endogenous locus, via 
homologous recombination in mouse embryonic stem cells 
or directly in zygotes via CRISPR/Cas9 genome editing. 
At the smallest scale, targeted knock-in has been used to 
introduce point mutations associated with human TDP43-
ALS into the endogenous mouse TARDBP gene (Fratta 
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Table 1  Genetically humanised neurodegeneration mouse models referred to in the text
Disease Model (gene) Referred to in
Transgenics AD/tauopathy 5xFAD (APP, PSEN1) Choi et al. (2018), Devi et al. (2010), Neuner et al. 
(2019)
APPPS1 (APP, PSEN1) Ali et al. (2018), Bacioglu et al. (2016), Espuny-
Camacho et al. (2017), Lesuis et al. (2018), Liao 
et al. (2018), McGinley et al. (2018), Wang et al. 
(2003)
APPSw-NSE (APP) Lee et al. (2015)
3xTgAD (APP, PSEN1, MAPT) Ager et al. (2015), Blurton-Jones et al. (2009), Hala-
gappa et al. (2007), Hirata-Fukae et al. (2008))
hTau (MAPT) Gratuze et al. (2017)
J20 (APP) Lee et al. (2018)
Tg2576 (APP) Callahan et al. (2001), Dong et al. (2004), Farr 
et al. (2014), Kim et al. (2015), Lee et al. (2002), 
Schafer et al. (2015)
P301S-Tau (MAPT) Bacioglu et al. (2016), DeVos et al. (2017))
ht-PAC-E10 + 14 (MAPT) Sud et al. (2014))
HD R6/2 (HTT) Hockly et al. (2002)
R6/1 (HTT) Harrison et al. (2013), Pang et al. (2006))
YAC128 (HTT) Ehrnhoefer et al. (2018), Moreno et al. (2016)
C6R (HTT) Ehrnhoefer et al. (2018)
N171–82Q (HTT) Corrochano et al. (2018), Potter et al. (2010)
BACHD (HTT) Kordasiewicz et al. (2012), Monteys et al. (2017)
ALS SOD1-G93A (SOD1) Acevedo-Arozena et al. (2011), Ari et al. (2014), 
Bilsland et al. (2010), Deitch et al. (2014), Dupuis 
et al. (2004), Gaj et al. (2017), Garbugino et al. 
(2018), Goutman et al. (2015), Gurney et al. 
(1994), Hamadeh et al. (2005), Heiman-Patterson 
et al. (2005), (2011), Kang et al. (2013), McCamp-
bell et al. (2018), Olivan et al. (2014), Pfohl et al. 
(2015), Riar et al. (2017), Williams et al. (2009a), 
Zhao et al. (2006)
SOD1-L126delTT Watanabe et al. (2005)
C9-BAC (C9orf72) Liu et al. (2016)
Prp-TDP-43-A315T (TARDBP) Coughlan et al. (2016)
TDP-43-A315T, -G348C (TARDBP) Pozzi et al. (2019)
hgFUS-R521C, -R521H (FUS) Lopez-Erauskin et al. (2018)
PD A53T-αS, A30P-αS (SNCA) Bacioglu et al. (2016)
SMA hSMN2 (SMN2) Hua et al. (2011), Passini et al. (2011), Porensky 
et al. (2012), Williams et al. (2009b)
Targeted to non-endogenous locus ALS Tau-ON-hFUS-P525L (FUS) Sharma et al. (2016)
TDP-43-M337V-ROSA26 (TARDBP) Gordon et al. (2019), Sleigh et al. (2018)
Targeted to endogenous locus AD APP-NL, -NL-F, -NL-G-F (APP) Saito et al. (2014)
hAPOE2, -E3, -E4 (APOE) Huynh et al. (2017), Knouff et al. (1999), Liao et al. 
(2018), Shi et al. (2017), Sullivan et al. (1997), 
(1998)
HD CAG140 KI (HTT) Stefanko et al. (2017)
HDH(CAG)150 (HTT) Heng et al. (2007)
ALS FUS-Delta14 (FUS) Devoy et al. (2017), Sleigh et al. (2018)
Whole chromosome humanisation DS Tc1 (Chr. 21) Deveson et al. (2018), O’Doherty et al. (2005), 
Wilson et al. (2008)
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et al. 2018; White et al. 2018). Physiological humanised 
models are now also being generated via targeted replace-
ment of mouse sequences by orthologous human sequences 
(Zhu et al. 2019). Such physiological humanised knock-in 
models include those for studying AD, whereby finescale 
humanisation of only a handful of mouse amino acids in the 
amyloid precursor protein (APP) encoded by the mouse App 
gene, resulted in a fully human amyloid beta peptide; and 
recreating unique human biochemistry, such that these mice 
provide an excellent physiological model of human amyloid 
beta protein deposition (Saito et al. 2014). Going further, 
whole genes (Leidy-Davis et al. 2018; Wallace et al. 2007) 
and entire gene clusters (Lee et al. 2014; Macdonald et al. 
2014) can now be humanised by genome engineering. At the 
largest scale, genetic humanisation can be achieved by inte-
gration of entire human (or human artificial) chromosomes 
via microcell-mediated chromosome transfer, a technique 
which has been used to model human trisomy 21 that gives 
rise to Down syndrome (O’Doherty et al. 2005).
We note that non-coding sequences, including the promo-
tors, may be different between mouse and human resulting in 
species-specific differences in gene expression that in some 
cases will affect phenotypes (Deveson et al. 2018). Genomi-
cally humanised mouse models that include promotors can 
start to tease out these effects (Wilson et al. 2008).
Cellular humanisation: generating human: mouse chimeras 
at the tissue level
The advent of human iPSCs has enabled patient-specific 
disease-in-a-dish modelling, but 2D or even 3D culture sys-
tems cannot recapitulate the complexity of the CNS in vivo. 
Furthermore, the differentiation of human iPSCs into mature 
CNS cell types beyond an embryonic-like state (and capa-
ble of developing age-related neurodegenerative phenotypes) 
has proved to be challenging (Vera and Studer 2015). How-
ever, studies of chimeras show a variety of human iPSC-
derived neural or glia precursors survive, differentiate into 
diverse lineages, mature, and functionally integrate when 
engrafted into the mouse brain or spinal cord (Chen et al. 
2015, 2016; Espuny-Camacho et al. 2013; Goldman et al. 
2015; Krencik et al. 2011; Wang et al. 2013). These chimeric 
humanised cellular models can be used to study cell intrinsic 
pathogenic mechanisms of neurodegeneration within patient 
iPSC-derived human CNS cells in vivo in the context of the 
amazingly complex mouse brain.
Patient-derived cells used may not necessarily be neurons. 
In human:mouse glia chimeras, the engrafted human glia 
precursors outcompete their mouse counterparts, such that 
over time the chimeric mice harbour an astroglial network 
dominated by human astrocytes. Models of hypomyelination 
can harbour an almost fully humanised oligodendrocyte net-
work (Goldman et al. 2015; Krencik et al. 2011; Wang et al. 
2013; Windrem et al. 2014). Furthermore, human astrocytes 
are distinct with respect to their size, complexity, and diver-
sity; attributes that can be recapitulated in human:mouse glia 
chimeras in vivo and may be significant for human neuro-
degenerative processes (Chen et al. 2015; Han et al. 2013; 
Krencik et al. 2011; Oberheim et al. 2009).
Four components of phenotype
Is there a role for the standardised, usually inbred, labo-
ratory mouse to help us reach strategic decisions about 
human healthcare for subpopulations in real life? We believe 
humanised mouse models are already doing so, and must be 
a part of precision medicine networks in the future.
Here, we consider how mouse models of neurodegen-
eration contribute to precision medicine, looking at four 
major factors that can affect phenotype: genetics (including 
monogenic causative mutations, epigenetics, and the effect 
of genetic background), environment, ageing, and stochas-
ticity. We then consider the contribution of these models to 
therapies.
Genetics
Mouse models pave the way for understanding 
pathomechanism related to individual mutations
Genetically mutant mice have been used for decades to 
model and drill into fundamental pathogenic mechanisms 
for a wide spectrum of human monogenic neurodegenera-
tive disorders, and so we do not discuss them in detail here.
Some neurodegenerative disorders, such as HD or other 
polyglutamine disorders, are defined both by their clinical 
presentation and a singular genetic alteration. Other diseases 
including ALS/FTD, AD, and PD are defined principally by 
their clinical presentation, and have heterogeneous causative 
mutations. For example, > 25 genes can cause dominantly 
inherited monogenic familial ALS and/or FTD, although 
we do not yet understand the genetic changes conferring 
susceptibility in most sporadic ALS cases (90% of patients). 
Humanised genetic mouse models have provided vital 
insights into the pathomechanisms underlying ALS, showing 
that mutations in different genes cause distinct pathological 
changes—from toxic protein accumulation (Liu et al. 2016) 
to cytoplasmic mislocalisation of RNA-binding proteins 
(Devoy et al. 2017; Gordon et al. 2019; Sharma et al. 2016) 
to axon transport deficits (Bilsland et al. 2010; Sleigh et al. 
2018) to defective protein synthesis (Lopez-Erauskin et al. 
2018) to the involvement of oligodendrocytes (Kang et al. 
2013), and many other alterations (Taylor et al. 2016)—that 
may lead to motor neuron degeneration and/or FTD.
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Humanised mouse models can be used to model indi-
vidual patient mutations, including rare mutations, such as 
the SOD1-L126delTT mutation found in a single Japanese 
family with distinctive ALS pathology among SOD1 muta-
tion carriers (Watanabe et al. 2005), and the aggressive 
FUS-Delta14 mutation from a single sporadic early-onset 
ALS patient modelled in mice through a partial humanisa-
tion knock-in strategy (Devoy et al. 2017). These diverse 
models will give us a better understanding of the function 
of different genes implicated in neurodegenerative diseases, 
and how different mutations in the same gene can impact on 
disease pathology and the potential implications for treat-
ment. Modelling rare variants with humanised sequence will 
be particularly useful in developing therapies that target spe-
cific human mutations, mutant transcripts, or proteins.
These mechanistic studies provide invaluable informa-
tion to help in predicting which patients may be responsive 
to specific therapies. Historically, in clinical drug trials for 
neurodegenerative disorders, treatments have not stratified 
patients by the underlying genetic causes, although the land-
scape is changing and humanised mouse studies are guid-
ing more precise approaches. For example, arimoclomol 
is a drug that induces the heat shock protein response and 
was shown to be effective at ameliorating neuromuscular 
pathology and function in SOD1-G93A mice, and is now 
in clinical trials for SOD1-ALS patients (Benatar et al. 
2018; Kieran et al. 2004). This approach may be essential 
for achieving significant treatment efficacy, in particular for 
treatments that target underlying mechanistic causes, which 
are diverse and likely linked to specific genetic factors.
The consequences of genetic variation
Humans are considerably more variable at the genetic level 
than inbred laboratory mice and this affects clinical out-
come at all levels and thus decisions about precision medi-
cine. Different alleles of a single modifier gene may radi-
cally affect our susceptibility and response to disease. For 
example, the APOE locus (encoding Apolipoprotein E which 
functions in lipoprotein metabolism) has three variants (dif-
fering at 2 residues) in the human population (APOE2, -E3, 
and -E4), each of which has dramatic effects on risk for both 
late-onset AD (-E4 confers risk) and cardiovascular disease 
(-E4 also confers risk, as does the rare-E2/-E2 haplotype 
that also confers risk for hyperlipoproteinemia). These risks 
are imparted through varying affinities for lipoproteins and 
lipoprotein receptor-binding capabilities: both the -E2 allele 
and common-E3 allele preferentially bind to small phospho-
lipid-enriched high-density lipoproteins, although APOE2 is 
defective in binding to lipoprotein receptors, while APOE4 
distinctly binds larger triglyceride-enriched very low-density 
lipoproteins (Mahley 2016). Mice only have the ancestral 
-E4 variant, although evolutionary divergence between 
mouse and human results in this allele behaving similarly 
to the lower risk human -E3 allele (i.e. affinity for high-
density lipoproteins). Targeted genomic humanisation via 
knock-in to replace the endogenous mouse locus with each 
of the three human variants resulted in the humanised vari-
ants binding lipoproteins as they do in humans (Knouff et al. 
1999; Sullivan et al. 1997, 1998), providing a unique toolkit 
to understand the distinct impact of these alleles on disease. 
With respect to neurodegeneration, humanised APOE mice 
have uncovered pathomechanisms specific to -E4 carriers, 
showing that the presence of APOE4 aggravates tau-medi-
ated neurodegeneration and neuroinflammation (Shi et al. 
2017).
Genetic background, whether mouse or human, is critical 
for modulating disease. Modifier genes, defined as genes that 
are not disease causative, but can modulate disease outcomes 
ranging from susceptibility to onset to disease progression, 
play a major role in pathogenesis. However, we largely study 
mice on a single inbred genetic background, akin to study-
ing disease in a single patient. Some studies have looked 
at the effects of different inbred genetic backgrounds on 
mouse models of disease, for example, as in SOD1-G93A 
ALS mice, demonstrating strain-specific effects on disease 
onset, progression, and lifespan (Acevedo-Arozena et al. 
2011; Heiman-Patterson et al. 2011). A recent study used 
the BXD genetic reference panel of recombinant inbred 
strains—derived from C57BL/6 and DBA/2 lines segregat-
ing for > 4.8 million SNPs—to understand how background 
genetic variation can impact AD, using crosses to human-
ised 5xFAD transgenic mice (a model of amyloid deposi-
tion) (Neuner et al. 2019). Genetic background modified 
the expressivity of known late-onset AD-risk alleles, and 
modified the expressivity of cognitive phenotypes, similar 
to the variation seen in human AD. This included a DBA/2 
parental SNP in APOE associated with poorer performance 
in contextual fear acquisition. Furthermore, transcriptomic 
changes in aged AD-BXD mice showed higher concord-
ance with transcriptomic profiles from late-onset AD patient 
data sets, compared to inbred AD models. Thus, humanised 
mouse models incorporating genetic variability can improve 
the modelling of complex human diseases and provide a 
valuable tool to understand genetic modifiers of disease, 
and how these impact on treatment strategies for individual 
patients.
Cellular humanisation offers a unique perspective into 
understanding how human cells, from any given genetic 
background, succumb to neurodegeneration. Recently, the 
fate of GFP expressing human PSC-derived cortical neuron 
precursors engrafted into the brains of neonatal transgenic 
AD mice (APPPS1) was studied in relation to resident host 
neurons (Espuny-Camacho et al. 2017). APPPS1 mice dis-
play early-onset amyloid pathology, but minimal neuron 
loss (Radde et al. 2006); in contrast, human PSC-derived 
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engrafted neurons, exposed to host amyloid beta plaques, 
underwent significant neuronal death by 6 months of age 
accompanied by signs of neuroinflammation and neurotic 
dystrophy (Espuny-Camacho et  al. 2017). As controls, 
no neuron loss was observed in mouse neurons engrafted 
into APPPS1 mice, nor in human neurons engrafted into 
wildtype mice. Thus, human cortical neurons are distinctly 
vulnerable to non-cell autonomous neurodegeneration pro-
cesses associated with amyloid beta plaque exposure com-
pared to mouse neurons. This study highlights that trans-
planting healthy cells into host-patient brains (i.e. for cell 
replacement therapy) with an advance diseased state may be 
ineffective for AD, as disease pathology could be transmitted 
from cell to cell.
This model system, combined with patient-derived 
iPSCs, offers the opportunity to analyse AD neurodegenera-
tion within individuals or groups with distinct genetic back-
grounds. Indeed, the authors demonstrated enhanced neuro-
degeneration of iPSC-derived human neurons from a patient 
with an FTD-causing MAPT mutation, exceeding the neuron 
loss observed in healthy human iPSC-derived neuron chime-
ras (Espuny-Camacho et al. 2017), thus providing insight 
into human-specific cell-autonomous pathomechanisms.
Human:mouse glia chimeras using patient iPSC-derived 
glia precursors engrafted into healthy donor mice have been 
successfully used to model ALS, DS, and HD in the genomic 
and cell-autonomous context of individual patients’ astro-
glia (Benraiss et al. 2016; Chen et al. 2014, 2015; Osipo-
vitch et al. 2019; Qian et al. 2017). Similarly, generation 
of human:mouse neuronal chimeras (Chen et  al. 2016; 
Espuny-Camacho et al. 2013) using patient iPSC-derived 
neuronal precursors has been used to model DS neurode-
generative processes within the context of individual patient 
cortical neuron dynamics (Real et al. 2018). The next step 
is to model these processes with genetically divergent 
human iPSCs, into genetically divergent host mice, to see 
the full spectrum of biological complexity that gives rise to 
neurodegeneration.
Risk associated with sex
Another genetic modulator of disease phenotype is sex, 
which alters risk for many neurodegenerative disorders, 
including AD (increased female risk) and PD and ALS 
(both with increased male risk). The reasons underlying 
these differential risks are not understood, but could be 
related to steroid sex hormone differences during develop-
ment and/or during adult life impacting on brain morphol-
ogy and function (Qiu et al. 2018), metabolism (Zhao et al. 
2016), or cellular processes such as autophagy (Congdon 
2018). Studies in humanised transgenic mouse models of 
AD (examples include Tg2576, 3xTgAD, APPPS1, and 
5xFAD models) have underpinned the differential gender 
risk by uncovering differential development of pathological 
changes, including an earlier onset of amyloid beta deposi-
tion, increased amyloid beta production, and more aggres-
sive amyloid beta pathology in female model mice (Callahan 
et al. 2001; Hirata-Fukae et al. 2008; Wang et al. 2003). 
Humanised mouse models have been used to dig deeper into 
mechanism; for example, pathological differences have been 
attributed to female-specific age-related increases in synap-
tic zinc, thought to contribute towards the aggregation of 
amyloid beta (Lee et al. 2002). Additionally, stress, which as 
discussed below acts as an environmental risk factor for AD, 
has been shown to drive marked female-specific increases 
in amyloid pathology in the hippocampus, associated with 
increased levels of in APP and BACE1 (cleaves APP to 
produce amyloid beta), in an AD mouse model (Devi et al. 
2010). Overall, these marked pathological and mechanistic 
differences between the sexes suggest that AD treatments 
may need to be tailored to gender; backed up by a study in 
AD mice showing that calorie restriction ameliorated pathol-
ogy only in females (Schafer et al. 2015).
In the widely used SOD1-G93A humanised transgenic 
ALS model, female mice exhibit later onset of disease and 
prolonged survival versus males in some but not all inbred 
strains, demonstrating genetic background-dependent 
effects, consistent with an increased incidence of ALS in 
males (Heiman-Patterson et al. 2005; Pfohl et al. 2015). 
Female-specific protection was subsequently linked to the 
estrogen-receptor alpha-mediated mitochondrial unfolded 
protein response (Riar et al. 2017).
Ultimately, studies in both sexes in humanised mouse 
models of neurodegeneration will serve to understand vul-
nerabilities or protective mechanisms associated with sex 
that can aid in the development of new treatments (Turner 
2001). These and human studies also highlight the need 
to stratify clinical trials by sex to reflect sex differences in 
disease pathology and mechanism, and to more accurately 
assess the efficacy of treatments.
Environment
Even in the (fairly rare) neurodegenerative diseases caused 
by a highly penetrant monogenic mutation, environmental 
factors have a role in determining outcomes (penetrance, 
severity, onset of disease). For example, phenotype in mono-
genic humanised genetic mouse models of HD (R6/2) can 
be improved by environmental enrichment (such as intro-
ducing toys, ladders, varied bedding), in ways we need to 
better understand, to give best advice about lifestyle while 
treatments are being developed in humans (Hockly et al. 
2002). The long-term effects of almost everything we con-
sider important for human disease manifestation, includ-
ing early life stress, can be tested in mice—with the rather 
large proviso that mice have their own biology, including 
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species-specific behaviours, and are not simply small 
humans.
One key area in which humanised mice can tell us about 
the effects on environment lies in the study of weight, metab-
olism, and diet. Weight is an important trait in all human 
neurodegenerative disorders. Alterations in weight reflect 
changes in whole-body metabolism induced by disease 
(Kitamura et al. 2017; Mariosa et al. 2017; Nordestgaard 
et al. 2017; Singh-Manoux et al. 2018) and body weight 
alterations (i.e. weight loss or weight gain) are common 
comorbidities found in neurodegenerative disease (Djousse 
et al. 2002; Emmerzaal et al. 2015; Hu et al. 2006; van der 
Burg et al. 2017; Wills et al. 2016). It is therefore not sur-
prising that obesity and type II diabetes are risk factors for 
AD (Singh-Manoux et al. 2018). Conversely, higher Body 
Mass Index at onset and reduced weight loss through disease 
progression are beneficial in ALS (Peter et al. 2017). The 
weight of an individual is also a complex trait, pre-deter-
mined by genetics as well as environmental interaction (such 
as diet) and time-associated changes (ageing).
The study of external environmental contribution to 
weight and metabolic balance, through controlled diet, is 
an important entire field of research (Pistollato et al. 2018), 
not only in neurodegenerative diseases, but in other complex 
disorders, including diabetes, cardiovascular disease, and 
cancer. For precision medicine, it is being championed by 
the emerging field of Nutrigenomics, which focuses on the 
interaction of diet and genetics, and how specific genetic 
profiles can help determine the nutritional needs of individu-
als, in health and disease.
Many studies on nutrition and age-related disease, 
including many forms of neurodegeneration, incorporate 
dietary caloric restriction, as this appears to extend lifes-
pan by stimulating autophagy via expression of Sirtuin 
1 (Morselli et al. 2010). Dietary restriction, or related 
interventions such as intermittent fasting, have proven 
effective at ameliorating phenotypes in preclinical studies 
with genetically humanised HD (YAC128, C6R) and AD 
(3xTgAD) mouse models (Ehrnhoefer et al. 2018; Hala-
gappa et al. 2007; Moreno et al. 2016). However, caloric 
or dietary restriction is not beneficial in every context, and 
mouse models are of enormous value to understanding 
how such interventions may be beneficial in the human 
population. For example, caloric restriction exacerbated 
tau aggregation in the brain of an obese humanised tau 
mouse model (htau) (Gratuze et al. 2017), and dietary 
restriction is detrimental in the SOD1-G93A ALS mouse 
model (Hamadeh et al. 2005). Accordingly, a ketogenic or 
high-energy diet is protective in SOD1-G93A mice (Ari 
et al. 2014; Dupuis et al. 2004; Olivan et al. 2014; Zhao 
et al. 2006), and similarly for humanised Prp-TDP-43-
A315T transgenic mice (Coughlan et al. 2016). Aside from 
modulating foods associated with energy metabolism, 
dietary supplementation with antioxidants has also been 
shown to be beneficial in humanised AD (APPPS1) mice 
(Ali et al. 2018).
Tied in with metabolism, weight, and diet is exercise, 
which may prove an important consideration for preci-
sion medicine strategies for many neurodegenerative dis-
eases. Exercise is considered beneficial by improving car-
diovascular health and strength, and boosting metabolism 
through effects on skeletal muscle (Booth et al. 2015), but 
has other benefits associated with neurological function, 
including improving mental health and cognition. Physi-
cal inactivity is a major risk factor for AD (Norton et al. 
2014), and the benefits of exercise for AD have been exten-
sively studied in genetically humanised mice (Shepherd 
et al. 2018). For example, in humanised 5xFAD AD ani-
mals, exercise induced cognitive benefit through increas-
ing adult hippocampal neurogenesis and elevating BDNF 
levels, so providing a novel AD therapeutic avenue (Choi 
et al. 2018). Similarly, in humanised mouse models of HD 
(R6/1 and CAG140 KI mice), exercise primarily improv-
ing cognitive functions (Harrison et al. 2013; Pang et al. 
2006; Stefanko et al. 2017). However, the form of exercise 
could be critical: for example, prolonged strenuous exer-
cise was detrimental for motor-function and lifespan in 
humanised HD (N171–82Q) mice (Corrochano et al. 2018; 
Potter et al. 2010); perhaps not surprisingly given that HD 
is a neuromuscular wasting disorder. Similarly for ALS, 
another neuromuscular wasting disorder, negative effects 
of exercise have been shown in SOD1-G93A ALS mice 
(Garbugino et al. 2018), consistent with a recent patient 
study that found a positive correlation between physical 
activity and risk for developing ALS (Visser et al. 2018).
Finally, stress is also a crucial factor modulating the 
onset and progression of neurodegenerative disease, as 
well as many other pathologies. It has been demonstrated 
that exposure of AD humanised mouse models to differ-
ent kinds of stressors exacerbates both intracellular and 
extracellular pathologies associated with AD (reviewed 
in (Justice 2018)). For example, isolation stress increased 
amyloid beta deposition and perturbed memory in AD 
(Tg2576) mice (Dong et al. 2004). Similarly, in another 
AD (APPPS1) mouse model, early life stressors increased 
amyloid pathology and impaired cognitive performance in 
12-month old mice, responses that could be prevented by 
transient blocking of glucocorticoid receptors, providing a 
potential therapeutic intervention targeting glucocorticoid 
hormonal increases that occur in response to stress (Lesuis 
et al. 2018). While stress is principally environmental, 
individual responses to physical and mental stressors 
partly depend on patient-specific genetic and epigenetic 
traits, which should also be considered from a precision 
medicine standpoint.
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Ageing
Ageing is the major risk factor for almost every neurodegen-
erative disorder. The exact correspondence of human and 
mouse ages may be debated, but for most strains, 3 months 
of age is a young adult and a mouse over 18 months of age 
is considered ‘old’. While there are clearly huge differences 
between human and mouse in rates of ageing and of lifes-
pans, we share the effects of senescence, defined by ‘bio-
markers’ such as loss of pigment in the hair and weight gain. 
Thus, ageing mice in health and disease provide a model 
system for studying ageing, including effects on neurode-
generation. As with all phenotypes, lifespan and rate of age-
ing depend on the genetic background of the mouse, with 
a long-lived strain such as C57BL/10 living for an average 
of 826 days for males and 693 days for females, whereas 
BALB/c live on average 539 for males and 575 for females 
(Festing 1979). Indeed, the SAM inbred strains were devel-
oped to be either senescence-prone (SAMP) or senescence-
resistant (SAMR), specifically for studies of age-related phe-
notypes (Takeda 2009; Takeda et al. 1981), and these mice 
have provided a model to study the transition from healthy 
ageing to neurodegeneration, notably in AD (Diaz-Moreno 
et al. 2018).
For modelling neurodegenerative disease, mice need 
to have a relevant mutation, and they need to be studied 
at a range of ages. Overexpression mutants with human 
transgenes are the still the most widely used models of neu-
rodegeneration but they may have a severe disease, some-
times with a relatively short lifespan that can make study 
of ageing-related processes difficult. As discussed above, 
‘low-copy’ transgenics can exhibit a slower disease course, 
but gene dosage is often still artificially high; for example, 
‘low-copy’ SOD1-G93A mice have between 4 and 10 cop-
ies of human SOD1 (Acevedo-Arozena et al. 2011; Deitch 
et al. 2014). However, the use of knock-in models that have 
a slower rate of progression, with physiological expression 
of the mutation, is more informative for both early-stage dis-
ease processes and for following the effects of ageing; such 
models include genetically humanised FUS-ALS (Devoy 
et al. 2017) and HD (Heng et al. 2007) knock-in mice that 
exhibit age-dependent, progressive neurodegeneration.
A key issue for precision medicine and modelling human 
disease is how age affects the efficacy of treatments. For 
example, the effect of physical exercise has been debated 
in ALS and in AD as above. Studies in mouse and human 
show that physical exercise may reduce risk of AD, but a 
recent large patient study showed exercise had no positive 
effect (and may have negative effects) (Shepherd et al. 2018). 
Thus, while lifelong exercise may have beneficial effects 
with regard to AD risk, exercise in older age in patients 
should be viewed independently. In the context of precision 
medicine, it is possible that particular exercise regimes may 
be beneficial in some patients, but we need considerably 
more studies of age effects, genetics, exercise regime, etc. 
to draw conclusions. However, this area is vitally important, 
because exercise is a relatively straight-forward and cheap 
treatment that does not require patient hospitalisation.
Stochastic factors
A recent study showed that random somatic mutation in the 
brain contributes to development of sporadic AD, through 
the creation of multiple reverse-transcribed copies of APP 
reinserted into the genomes of individual neurons, as discov-
ered in human brain samples and a humanised AD mouse, 
(J20 transgenic animals, which overexpresses human APP 
with 2 AD mutations) (Lee et al. 2018). Thus, stochastic 
events (closely tied to ageing) may have a profound disease 
causative effect in neurodegenerative disease, as is the case 
in cancer. How we model this in the mouse nervous sys-
tem, to corroborate cause and effect and to further explore 
mechanism, is to be determined, but lessons can be learned 
from cancer research, where researchers have engineered 
sophisticated mouse models that produce somatic mutations, 
to pave the way for therapies for human disease (Fisher et al. 
2009; Maresch et al. 2016; Sanchez-Rivera et al. 2014).
Precision medicine experts (in computational biology and 
other fields) can help model and understand how stochas-
tic events contribute to disease processes in human and in 
mouse. This is essential for our understanding of mecha-
nism: for example, human data on ALS have shown that at 
least some forms may require six genetic lesions or ‘hits’ 
through life, to result in this neurodegenerative disease (Al-
Chalabi et al. 2014).
Humanised mouse models for therapeutic 
strategies in precision medicine
Gene therapy is a promising new approach for the treat-
ment of neurodegenerative disease. Therapies utilising 
antisense oligonucleotides (ASOs), a method of gene 
silencing, have the potential to ameliorate a range of neu-
rodegenerative disorders. ASO-based strategies rely on 
binding to complementary RNA, hence humanised genetic 
models of neurodegeneration, which carry human coding 
sequences of interest, are an ideal system for preclini-
cal testing. For example, ASOs, administered typically 
via intraventricular or intrathecal injection, have proven 
effective at silencing pathogenic gene products in geneti-
cally humanised mouse models of ALS (McCampbell 
et al. 2018), HD (Kordasiewicz et al. 2012), AD (Farr 
et al. 2014), and tauopathy (DeVos et al. 2017; Sud et al. 
2014). Genetically humanised mice have also been used 
to assess the impact of a known modifier gene for AD, 
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APOE4: ASO administration to double-humanised APOE 
(knock-in)/APPPS1 (transgenic) AD mice resulted in suc-
cessfully reducing amyloid beta plaque pathology in both 
-E4/E4 (risk associated) and -E3/E3 (non-risk associated) 
mice, but only when applied before the onset of amyloid 
deposition, offering a valuable perspective on the utility 
of this treatment in the general population, and the need to 
carefully time treatments in human patients (Huynh et al. 
2017). Notably, an ASO approach tested extensively in 
genetically humanised transgenic SMN2 mice (a gene not 
present in mouse) blocks an intronic splicing silencer in 
human SMN2, which increases full-length SMN2 isoform 
expression and compensates for loss of SMN1 that causes 
SMA (Hua et al. 2011; Passini et al. 2011; Porensky et al. 
2012; Williams et al. 2009b). These pioneering mouse 
studies have been used as proof of principle to drive many 
of these therapies into clinical trials, and in the case of 
SMN2 ASO therapy, approval for clinical use (Schoch and 
Miller 2017).
The emergence of CRISPR/Cas9 technology is providing 
an opportunity to correct or nullify pathogenic genes perma-
nently at the genomic level. Similar to the above-mentioned 
mRNA-based targeting strategies, genetically humanised 
mice offer the perfect model system for preclinical testing 
of gene-editing approaches that can be directly translated 
to the clinic. Recently, an AAV-based delivery of CRISPR/
Cas9 components has been proven to work effectively to 
reduce hSOD1 levels in the SOD1-G93A humanised mouse 
model, delaying disease onset and extending survival (Gaj 
et al. 2017), again providing proof of principle for clinical 
trials.
A third major therapeutic use of humanised mice is their 
use in testing immunotherapies that target human proteins. 
For example, AAV delivery of an human anti-TDP-43 anti-
body was recently shown to ameliorate pathology in human-
ised TARDBP transgenic (TDP-43-A315T, -G348C) mouse 
models (Pozzi et al. 2019). Similarly, for AD, an antibody 
specifically targeting aggregated forms of the AD-risk vari-
ant APOE4 was administered to APOE4/APPPS1 double-
humanised mice and shown to reduce amyloid beta deposi-
tion, implicating APOE4 aggregation in the formation of 
amyloid plaques (Liao et al. 2018). However, antibodies 
directly targeting amyloid beta have been tested in human-
ised mice for over two decades, and while some have pro-
gressed through to clinical trials, none have made it to clinic 
(Kohyama and Matsumoto 2015; Panza et al. 2019). Part 
of the disconnect between bench and clinic could be due to 
genetic heterogeneity among AD patients in trials versus the 
few rare forms of familial AD modelled in mice, highlight-
ing the need to better stratify and match patients to the types 
of mutations used in mice, at least in initial efficacy studies. 
Also, a more diverse set of animal models is warranted to 
better understand disease diversity in patients, and of course 
the timing of human disease manifestation and treatment 
may be different from testing cohorts of genetically similar 
mutant mice.
Cell replacement therapies (CRT) offer the potential to 
replace neurons lost to neurodegeneration, and thus retain 
or restore neurological function. Indeed, early CRT clinical 
trials to treat PD patients 3 decades ago showed promise, 
with human foetal ventral mesencephalon (hVM) engraft-
ments demonstrating notable motor improvements in small 
cohorts of patients (Freed et al. 1992; Lindvall et al. 1990; 
Spencer et al. 1992; Widner et al. 1992), although in sub-
sequent, larger trials patients failed to consistently respond 
positively, with some suffering adverse effects (Freed et al. 
2001; Olanow et al. 2003). Such therapy is still not routine 
today, likely due at least in part to the genetic and phenotypic 
heterogeneity of patients involved, highlighting the impor-
tance for research into the application of precision medicine 
to fine-tune CRT strategies. The use of animal models has 
a crucial role to play, not least in the development of the 
technology itself. Prior to the aforementioned clinical trials, 
pioneering preclinical work engrafting hVM tissue into a rat 
chemically induced PD model demonstrated vital proof of 
principle (Brundin et al. 1986). In more recent years, human 
PSCs (embryo derived or induced) are showing great prom-
ise as a potentially infinite source of cells for CRT, versus 
the very limited supply of human foetal tissue.
This promise is borne out in cellular humanisation animal 
studies whereby human PSC-derived dopaminergic neurons 
have been grafted into the brains of mouse, rat, and non-
human primate models of PD, with positive outcomes for 
ameliorating phenotypes (Grealish et al. 2014; Kikuchi et al. 
2017; Kriks et al. 2011; Roy et al. 2006), although the PD 
models were all chemically induced, and it may be prudent 
to test this treatment strategy in genetic models of disease. 
Nevertheless, human trials are on the horizon (Barker et al. 
2017).
In AD, similar efforts have been made to develop CRT 
using foetal human neural tissues, adult human neural and 
non-neural tissues, or human PSC-derived neural progeni-
tor cells (NPCs) engrafted into animal models (Fang et al. 
2018). Most of the models used in these preclinical AD stud-
ies are transgenic mice bearing human familial AD-mutated 
gene copies, and predominantly mutated human APP (Ager 
et  al. 2015; Blurton-Jones et  al. 2009; Lee et  al. 2015; 
McGinley et al. 2018). While this is encouraging, over 95% 
of AD cases are non-familial, caused by poorly understood 
interactions between multiple genetic variants (notably the 
3 human APOE variant alleles) and environmental/lifestyle 
factors; thus, the response to treatment in these patients is 
less predictable. It is likely that many patients (with specific/
distinctive AD pathogenic causative mechanisms) will not 
be responsive to a one-size-fits-all neural cell transplanta-
tion intervention. For example, astroglia make a significant 
Uses for humanised mouse models in precision medicine for neurodegenerative disease 
1 3
contribution to AD pathogenesis, through dysregulation 
of inflammation that can influence amyloid beta levels, or 
through production of APOE4 variants (astrocytes primarily 
produce APOE4 and regulate neuronal APOE) (Gonzalez-
Reyes et al. 2017; Harris et al. 2004; Oksanen et al. 2017). 
Thus, transplantation of neurons into an astrocyte-driven 
toxic environment may not be beneficial, whereas transplant 
of astrocytes or glial progenitor cells (GPCs) may be more 
appropriate (Goldman et al. 2015).
Furthermore, animal studies have already provided evi-
dence that stratifying disease by the largest risk factor for 
AD, age, dramatically impacts on treatment success (Kim 
et al. 2015), demonstrating the potential for predicting suc-
cess in patients considering other common risk factors, 
such as APOE4 carrier status, for which there are human-
ised mouse models readily available (Knouff et al. 1999; Liu 
et al. 2017; Shi et al. 2017).
Similar conclusions can be drawn for preclinical human 
xenograft studies for ALS, from which many studies have 
demonstrated improvements in transgenic mice and rats, 
paving the way for early clinical trials evaluating (and suc-
cessfully demonstrating) safety (Goutman et al. 2015, 2018). 
Preclinical animal studies were conducted almost exclu-
sively in SOD1-G93A transgenic rodents; however, SOD1 
mutations are only 2% of ALS cases (< 10% ALS cases are 
familial; ~ 20% of these have SOD1 mutations). Again, dis-
tinct genetic causes of ALS likely need distinct evaluation 
for treatment efficacy. Several mouse models for ALS exist, 
representing all the major ALS causative genes (C9orf72, 
SOD1, TARDBP, FUS, etc.), including new knock-in models 
discussed in this review (De Giorgio et al. 2019), which can 
be used to customise distinct strategies for CRT in patients.
The most likely, and plentiful, source of cells for CRT 
are human iPSCs; however, patient-derived autologous 
grafts bear a significant caveat—disease-causing mutations 
will remain and thus may retain pathological changes. One 
route around this problem is to correct pathological muta-
tions in iPSCs via gene editing. In many cases of dominant 
mutations, for example, the HD-causing Huntingtin allele, 
mutant-allele-specific editing is desirable to avoid target-
ing potentially essential non-pathogenic gene copies. This 
can be achieved through a precision medicine approach by 
CRISPR/Cas9 targeting SNP variants proximal to patho-
genic alleles (Chao et al. 2018; Shin et al. 2016). Such an 
approach has been validated in humanised genetic mouse 
models of HD (Monteys et al. 2017). However, this is not 
currently possible for the majority of AD, PD, and ALS 
patients who are ‘sporadic’ cases, as they do not carry 
known monogenic disease mutations.
Ultimately, early intervention or indeed prevention is 
the ideal therapeutic scenario. Humanised mouse models 
are proving their worth in understanding early neurodegen-
erative disease mechanisms, but the clinic needs to identify 
when these mechanisms have taken hold to inform when to 
begin therapies for individual patients and to identify dis-
ease onset as early as possible—and this means biomark-
ers. Biomarkers can also be used for stratification purposes 
to better understand disease diversity and how this might 
apply to treatment efficacy. The discovery and application of 
biomarkers to neurodegenerative diseases could ultimately 
help overcome the so-called “Valley of Death” effect, i.e. 
the failure to overcome between basic science and clinical 
application (Beach 2017). Humanised mouse models of neu-
rodegeneration provide a tool to study, in depth, the progres-
sion of neurodegenerative disease and to uncover hallmarks 
of presymptomatic, early, and late disease processes.
Indeed, humanised mouse models have made funda-
mental contributions in this area. For example, a study of 
microRNA expression changes in SOD1-G93A transgenic 
mice identified mir-206 upregulation as a reliable marker 
of disease onset in animals (Williams et al. 2009a), which 
has subsequently also been observed in ALS patients (Ricci 
et al. 2018). Additionally, three humanised mouse models 
representing AD, tauopathies, and α-synucleinopathies 
including PD were used to identify neurofilament light chain 
(NfL) as a marker of neurodegenerative disease progression 
(Bacioglu et al. 2016), which has recently been translated to 
patient studies demonstrating serum NfL as a presympto-
matic marker of familial AD (Preische et al. 2019).
Conclusion and speculation
We are all (humans and mice) the result of complex of 
genetic (including epigenetic) and environmental inter-
actions that occur pre-conception through to end of life. 
Humans and mice each have their own distinct advantages 
for medical research and we can (and should continue to) 
combine our understanding of both organisms to drive for-
ward our understanding of biology and pathology. Human 
studies give us vast datasets of sometimes non-rigorously 
defined phenotypes with considerable ethical, legal, and 
other issues of privacy. Mice give us equally vast datasets 
but usually in limited genetic backgrounds for limited tests. 
Utilising defined congenic strains are invaluable for pre-
cisely identifying interactions of different genetic compo-
nents—including pathogenic mutations, genetic background, 
and sex—with environmental variables and the process of 
ageing, without the confounding variable of genetic diver-
sity. Genetic and cellular humanised mice provide added 
physiological relevance and provide the best models for pre-
clinical testing of therapeutics. If we can integrate the advan-
tages of both human and mouse studies, this will greatly 
aid precision medicine for preventative and patient-based 
healthcare.
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For example, for clinical studies, humanised (and other) 
mice have clearly shown the need to stratify by genotype. 
ALS is the best illustration of this, where it is now clear 
that what appears to be a single disease, has over 25 differ-
ent monogenic forms, affecting many individual pathways. 
Therefore, treatments developed for the SOD1-G93A mouse 
cannot be presumed to work in patients with TARDBP-ALS, 
for example. Many familial forms of neurodegeneration are 
rare, and so in many cases we have very few patients in 
which to study pathomechanisms related to a given disease-
associated gene (for example, FUS mutations account for 
only ~ 4% of familial ALS cases). Furthermore, individual 
mutations within a given gene (i.e. rarer still, and in some 
cases only present in a single individual) may yield distinct 
disease outcomes that may inform precision medicine strate-
gies—in such cases, mouse models can provide the sample 
sizes to drill into pathomechanism with statistical clarity. 
Delineating phenotypes, pathological mechanisms, and bio-
markers according to specific genetic mutations in mice will 
aid greatly in informing stratification of patient groups to 
maximise the success of treatments in clinical trials.
Equally, for precision medicine studies, there is much to 
be learnt from the mouse studies as Lloyd and colleagues 
point out (Lloyd et al. 2015): the kind of large-scale, well-
networked, high-throughput analysis that is essential for 
precision medicine (Berlin et al. 2017), is relatively routine 
(at least on a smaller scale) for the mouse community. Thus, 
we can use this experience to contribute to discussions about 
data management, accessibility, standardisation of pheno-
typing, etc. This also includes identification and analysis of 
critical metadata. Perhaps, the only area where the mouse 
and in particular humanised mouse models cannot contribute 
is in the issue of privacy and informed consent.
Equally, human diversity clearly highlights how we limit 
our understanding of neurodegeneration by working on sin-
gle inbred lines, and the new finding of novel somatic muta-
tion in AD, for example (Lee et al. 2018), illustrates how 
we will likely need new paradigms for modelling human 
neurodegeneration.
Finally, in studying humanised mouse models of neurode-
generation, we need to choose our model carefully. Genetic 
mouse models allow us to look at a systems level on the 
often underappreciated pleiotropic effects of mutation, and 
we now have the tools to engineer refined humanised alleles 
expressing mutated proteins at physiological levels. In com-
parison, humanised cellular mouse models are tissue- and 
cell-type specific in their humanisation, but capture a snap-
shot of human genetic heterogeneity, while also capturing 
unique attributes of human cells in an in vivo setting—for 
example, the unique vulnerability of human neurons or the 
complexity of human astrocyte subpopulations and con-
nections—that cannot easily be achieved in genetic mouse 
models or in human cells in vitro. Combining these systems 
can offer even more powerful models to study human neu-
rodegeneration in vivo, in cell autonomous and non-cell-
autonomous contexts (Espuny-Camacho et al. 2017), and 
also provides excellent preclinical models to test therapeu-
tics such as CRT.
If precision medicine is based on reviewing all the evi-
dence to choose the optimal treatment for patients, then 
mouse studies must be included in this evidence. And of 
course, this is not only for treatment, but also for both pre-
vention and diagnosis.
Box 1. neurodegenerative diseases referred 
to in the text
Alzheimer’s disease, AD AD is the most common form of 
dementia, accounting for ~ 2/3 of people with dementia. 95% 
of those affected are over 65 years of age. Extracellular amy-
loid plaques and intracellular tau tangles are deposited in 
the brain leading to clinical outcomes that include loss of 
memory, apathy, and depression; progressing to an inability 
to express and communicate; physical symptoms can include 
immobility and seizures.
Amyotrophic lateral sclerosis, ALS ALS is a progressive 
neurological disorder characterised by loss of motor neu-
rons in the brain, brainstem, and spinal cord, resulting in 
weakness, muscle wasting, and ultimately respiratory failure. 
Symptoms usually present mid-late life with a disease course 
of approximately 5 years. The majority of ALS cases are 
sporadic (90%) with only a small proportion being familial 
(10%). ALS is genetically heterogeneous with more than 25 
causative genes identified.
Corticobasal degeneration, CBD CBD is a rare neurode-
generative disorder characterised clinically as corticobasal 
syndrome (CBS) and pathologically as CBD by the deposi-
tion of abnormal tau protein in the somatosensory, premotor, 
supplementary motor cortices, brainstem, and basal ganglia. 
CBS is a combination of cortical signs (e.g. apraxia, apha-
sia, frontal dementia, parietal lobe sensory signs) and basal 
ganglia signs (e.g. rigidity, akinesia, limb dystonia, postural 
instability). CBS symptoms largely overlap with other par-
kinsonian and dementing illnesses, such as PD, PSP, and 
AD, making it difficult to diagnose.
Down syndrome, DS DS is the most common chromo-
somal abnormality found in newborns, with an incidence 
of up to 1 in 750 live births, increasing with maternal age. 
DS is caused by trisomy of chromosome 21. Phenotypic 
features include several neurodevelopmental abnormalities 
and difficulties with motor skills, memory, and learning. 
DS patients are at a greatly increased risk of developing 
AD, principally due to an extra copy of APP, on chromo-
some 21. DS is also associated with many different phe-
notypic outcomes which vary greatly in penetrance, and 
in expressivity in the individual. These include cardiac 
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defects, gastro-intestinal diseases, periodontal diseases, 
and vulnerability to auto-inflammatory diseases.
Frontotemporal Dementia, FTD FTD is a group of 
related dementias resulting in brain atrophy of the frontal 
and temporal lobes, typically associated with behavioural 
changes and/or language impairments, and constituting a 
major, strongly inherited form of early-onset dementia. 
Onset is typically in mid-life, earlier than AD, and has a 
strong genetic and pathological overlap with ALS.
Huntington disease, HD HD is an autosomal-dominant 
neurodegenerative disorder caused by a polyglutamine 
tract expansion in the HTT gene, characterised by progres-
sive chorea, dystonia, and cognitive and psychiatric symp-
toms including dementia. There is progressive, selective 
neuronal cell loss and atrophy in the caudate and putamen, 
which can be seen radiographically. Age of onset is around 
30 years with a disease course between 5 and 20 years 
after the first clinical signs and symptoms are observed.
Parkinson’s disease, PD PD affects approximately 1% 
of the population over the age of 50 and is genetically het-
erogeneous with several loci identified causing PD. PD is 
progressive with onset in mid-to-late adulthood character-
ised by resting tremor, slowness of movements, muscular 
rigidity, bradykinesia, and postural instability; there may 
also be psychiatric features. Pathological features and his-
tological hallmarks of PD include the presence of Lewy 
bodies and α-synuclein deposition; in contrast, autosomal 
recessive juvenile Parkinson’s disease does not have Lewy 
body pathology.
Pick’s disease, PiD PiD is a neurodegenerative disorder 
and a form of frontotemporal lobar degeneration. PiD is 
clinically extremely difficult to differentiate from AD and 
clinical features also overlap with CBD and PSP. PiD can 
only be confirmed histopathologically by lobar or circum-
scribed atrophy, Pick cells, and tau-positive Pick bodies.
Progressive supranuclear palsy, PSP PSP is a rare neu-
rological disorder resembling PD. PSP has a wide clini-
cal spectrum including aberrant movement, posture, gait, 
speech, swallowing, eye movements, mood, behaviour, 
and cognition. Pathologically, PSP is characterised by tau 
neurofibrillary tangles primarily localised to subcortical 
regions neurons and glia, which differentiates it from AD.
Spinal muscular atrophy, SMA SMA is an autoso-
mal recessive neuromuscular disease affecting 1 in 
6000–10,000 live births, predominantly caused by loss of 
function of the SMN1 gene. SMA results in degeneration 
of the anterior horn cells of the spinal cord, symmetrical 
muscle weakness, and atrophy. SMA is divided into 4 sub-
groups depending on age of onset, phenotypic severity, 
and survival. Type I (“non-sitters”), type II (“sitters”), 
type III (“walkers”), and type IV (adult‐onset).
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